Recent advances in renal cell carcinoma from a pathological point of view

Shuji Mikami, Mototsugu Oya, Ryuichi Mizuno, Takeo Kosaka, Masaru Ishida, Naoto Kuroda, Yoji Nagashima, Ken ichi Katsube, Yasunori Okada

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The purpose of this article is to review the recent advances in renal cell carcinoma (RCC) from a pathological point of view. Because the genetic features and morphological characteristics have become major criteria for the classification of RCC, special techniques, such as immunohistochemistry, are essential to the differential diagnosis of renal tumors. Metastasis is frequently observed among the RCC patients with curative nephrectomy, and extracellular matrix-degrading enzymes, such as matrix metalloproteinases (MMP) and heparanase, play a key role in invasion and metastasis of RCC. Snail and Slug, transcription factors of epithelial-mesenchymal transition (EMT), accelerate cancer cell invasion through downregulation of E-cadherin and up-regulation of MMP. Therapies targeted at the vascular endothelial growth factor pathway have become the standard treatment of metastatic RCC. Although they lead to tumor shrinkage mainly by inhibiting angiogenesis, they have typically been associated with drug resistance. The mechanism of the resistance remains largely unknown, but complex events including re-activation of angiogenesis, EMT and cancer stem cells, and immune escape are implicated in the refractory response to the therapy. Recent advances of the research on RCC have caused the changes of classification and therapy, and pathologists should take overall view of these as integrated pathology.

Original languageEnglish
JournalPathology International
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Renal Cell Carcinoma
Epithelial-Mesenchymal Transition
Matrix Metalloproteinases
Neoplasm Metastasis
Neoplasms
Neoplastic Stem Cells
Cadherins
Therapeutics
Nephrectomy
Mesenchymal Stromal Cells
Drug Resistance
Vascular Endothelial Growth Factor A
Extracellular Matrix
Differential Diagnosis
Up-Regulation
Down-Regulation
Immunohistochemistry
Pathology
Kidney
Enzymes

Keywords

  • Cancer stem cell
  • Epithelial and mesenchymal transition
  • Molecular-targeted therapy
  • Renal cell carcinoma
  • Resistance

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Recent advances in renal cell carcinoma from a pathological point of view. / Mikami, Shuji; Oya, Mototsugu; Mizuno, Ryuichi; Kosaka, Takeo; Ishida, Masaru; Kuroda, Naoto; Nagashima, Yoji; Katsube, Ken ichi; Okada, Yasunori.

In: Pathology International, 2016.

Research output: Contribution to journalArticle

@article{a6315ccc2bb9468ebe3889079a01ab1d,
title = "Recent advances in renal cell carcinoma from a pathological point of view",
abstract = "The purpose of this article is to review the recent advances in renal cell carcinoma (RCC) from a pathological point of view. Because the genetic features and morphological characteristics have become major criteria for the classification of RCC, special techniques, such as immunohistochemistry, are essential to the differential diagnosis of renal tumors. Metastasis is frequently observed among the RCC patients with curative nephrectomy, and extracellular matrix-degrading enzymes, such as matrix metalloproteinases (MMP) and heparanase, play a key role in invasion and metastasis of RCC. Snail and Slug, transcription factors of epithelial-mesenchymal transition (EMT), accelerate cancer cell invasion through downregulation of E-cadherin and up-regulation of MMP. Therapies targeted at the vascular endothelial growth factor pathway have become the standard treatment of metastatic RCC. Although they lead to tumor shrinkage mainly by inhibiting angiogenesis, they have typically been associated with drug resistance. The mechanism of the resistance remains largely unknown, but complex events including re-activation of angiogenesis, EMT and cancer stem cells, and immune escape are implicated in the refractory response to the therapy. Recent advances of the research on RCC have caused the changes of classification and therapy, and pathologists should take overall view of these as integrated pathology.",
keywords = "Cancer stem cell, Epithelial and mesenchymal transition, Molecular-targeted therapy, Renal cell carcinoma, Resistance",
author = "Shuji Mikami and Mototsugu Oya and Ryuichi Mizuno and Takeo Kosaka and Masaru Ishida and Naoto Kuroda and Yoji Nagashima and Katsube, {Ken ichi} and Yasunori Okada",
year = "2016",
doi = "10.1111/pin.12433",
language = "English",
journal = "Pathology International",
issn = "1320-5463",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Recent advances in renal cell carcinoma from a pathological point of view

AU - Mikami, Shuji

AU - Oya, Mototsugu

AU - Mizuno, Ryuichi

AU - Kosaka, Takeo

AU - Ishida, Masaru

AU - Kuroda, Naoto

AU - Nagashima, Yoji

AU - Katsube, Ken ichi

AU - Okada, Yasunori

PY - 2016

Y1 - 2016

N2 - The purpose of this article is to review the recent advances in renal cell carcinoma (RCC) from a pathological point of view. Because the genetic features and morphological characteristics have become major criteria for the classification of RCC, special techniques, such as immunohistochemistry, are essential to the differential diagnosis of renal tumors. Metastasis is frequently observed among the RCC patients with curative nephrectomy, and extracellular matrix-degrading enzymes, such as matrix metalloproteinases (MMP) and heparanase, play a key role in invasion and metastasis of RCC. Snail and Slug, transcription factors of epithelial-mesenchymal transition (EMT), accelerate cancer cell invasion through downregulation of E-cadherin and up-regulation of MMP. Therapies targeted at the vascular endothelial growth factor pathway have become the standard treatment of metastatic RCC. Although they lead to tumor shrinkage mainly by inhibiting angiogenesis, they have typically been associated with drug resistance. The mechanism of the resistance remains largely unknown, but complex events including re-activation of angiogenesis, EMT and cancer stem cells, and immune escape are implicated in the refractory response to the therapy. Recent advances of the research on RCC have caused the changes of classification and therapy, and pathologists should take overall view of these as integrated pathology.

AB - The purpose of this article is to review the recent advances in renal cell carcinoma (RCC) from a pathological point of view. Because the genetic features and morphological characteristics have become major criteria for the classification of RCC, special techniques, such as immunohistochemistry, are essential to the differential diagnosis of renal tumors. Metastasis is frequently observed among the RCC patients with curative nephrectomy, and extracellular matrix-degrading enzymes, such as matrix metalloproteinases (MMP) and heparanase, play a key role in invasion and metastasis of RCC. Snail and Slug, transcription factors of epithelial-mesenchymal transition (EMT), accelerate cancer cell invasion through downregulation of E-cadherin and up-regulation of MMP. Therapies targeted at the vascular endothelial growth factor pathway have become the standard treatment of metastatic RCC. Although they lead to tumor shrinkage mainly by inhibiting angiogenesis, they have typically been associated with drug resistance. The mechanism of the resistance remains largely unknown, but complex events including re-activation of angiogenesis, EMT and cancer stem cells, and immune escape are implicated in the refractory response to the therapy. Recent advances of the research on RCC have caused the changes of classification and therapy, and pathologists should take overall view of these as integrated pathology.

KW - Cancer stem cell

KW - Epithelial and mesenchymal transition

KW - Molecular-targeted therapy

KW - Renal cell carcinoma

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84979734864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979734864&partnerID=8YFLogxK

U2 - 10.1111/pin.12433

DO - 10.1111/pin.12433

M3 - Article

C2 - 27461942

AN - SCOPUS:84979734864

JO - Pathology International

JF - Pathology International

SN - 1320-5463

ER -